This is a corporate earnings release, not a currency market report. It names no forex pair and reports no exchange-rate moves, pip figures or levels. Pharming Group reported third quarter 2026 total revenues of US$117.6 million, up 21% from the third quarter of 2025 and above market expectations. RUCONEST® revenue rose 14% to US$93.8 million, which the company attributed to demand stabilization and a seasonal inventory increase. Joenja® revenue climbed 58% to US$23.8 million, reflecting strong U.S. performance, although the source summary is truncated at that point. The headline also highlights Joenja's expansion in APDS and says CVID topline data is expected in November. The source does not mention central banks, macroeconomic data or currency effects. For forex traders, the release has no stated direct relevance and is primarily of interest to equity investors following the company.
News data provided by Marketaux.
ForexSentiment.live provides this summary as a convenience with proper attribution to the original source.
The full article is available at the original publisher's website.